Laboratory Costs in the Context of Disease (Laboratory Management) Laboratory Costs in the Context of Disease (Laboratory Management)

Laboratory Costs in the Context of Disease (Laboratory Management‪)‬

Clinical Chemistry 2000, July, 46, 7

    • $5.99
    • $5.99

Publisher Description

Rarely are patients hospitalized without some laboratory tests being performed, but the contribution of laboratory costs to the total costs of managing patients with different diseases has not been studied systematically. Because clinical laboratory costs, as a whole, can be readily quantified, they often become a focus of efforts to reduce expenditures in hospitals. The effectiveness of such moves has yet to be determined, although Winkelman (1) in 1984 established that laboratory costs do not decrease in proportion to the reduction of number of tests. No recent studies have been performed to verify that this is still true. Before the advent of diagnosis-related groups (DRGs) [1] in 1984, the prevailing fee-for-service approach to payments for services, including laboratory tests, encouraged excessive use of laboratory tests. There was no incentive for physicians or hospitals to be efficient in the use of tests because these generated income for the hospital. The laboratory was a revenue center for the hospital. The introduction of DRG transformed the laboratory into a cost center, with the cost of any test performed on a patient included in a DRG becoming an expense without offsetting revenue. However, instead of there being an immediate reduction in the number of tests performed, the ingrained habits of physicians continued so that ordering patterns largely went unchanged. More tests continue to be performed than probably are necessary for good management of patients. Reducing costs attributable to the laboratory would appear to be feasible both by curbing the number of tests performed and by reducing the costs of individual tests. Whereas laboratorians can influence the costs within the laboratory, few have tried to convince their clinical colleagues to change their ordering patterns. The most difficult challenge for both laboratorians and clinicians is to identify and eliminate, in advance, those tests that are not likely to have any direct influence on the diagnosis and/or management of the patient.

GENRE
Science & Nature
RELEASED
2000
1 July
LANGUAGE
EN
English
LENGTH
27
Pages
PUBLISHER
American Association for Clinical Chemistry, Inc.
SELLER
The Gale Group, Inc., a Delaware corporation and an affiliate of Cengage Learning, Inc.
SIZE
207.2
KB

More Books Like This

Effect of Disease Complications on Hospital Costs (Laboratory Management) Effect of Disease Complications on Hospital Costs (Laboratory Management)
2002
Comparative Costs of Treating Adults and Children Within Selected Diagnosis-Related Groups (Laboratory Management) Comparative Costs of Treating Adults and Children Within Selected Diagnosis-Related Groups (Laboratory Management)
2002
Near-Patient Test for C-Reactive Protein in General Practice: Assessment of Clinical, Organizational, And Economic Outcomes (Test Utilization and Outcomes) (Clinical Report) Near-Patient Test for C-Reactive Protein in General Practice: Assessment of Clinical, Organizational, And Economic Outcomes (Test Utilization and Outcomes) (Clinical Report)
1999
Financial Impact of Concurrent Coding (Cracking Codes) Financial Impact of Concurrent Coding (Cracking Codes)
2009
Applied Statistics for Medicine Applied Statistics for Medicine
2011
Improving Observation Status in a Hospital (Hospitals) Improving Observation Status in a Hospital (Hospitals)
2010

More Books by Clinical Chemistry

Lowering Cutoffs for Initial and Confirmation Testing for Cocaine and Marijuana: Large-Scale Study of Effects on the Rates of Drug-Positive Results (Drug Monitoring and Toxicology) Lowering Cutoffs for Initial and Confirmation Testing for Cocaine and Marijuana: Large-Scale Study of Effects on the Rates of Drug-Positive Results (Drug Monitoring and Toxicology)
1997
Myocardial Infarction Redefined: Role of Cardiac Troponin Testing (Editorial) Myocardial Infarction Redefined: Role of Cardiac Troponin Testing (Editorial)
2001
Distribution of Fasting Plasma Insulin, Free Fatty Acids, And Glucose Concentrations and of Homeostasis Model Assessment of Insulin Resistance in a Representative Sample of Quebec Children and Adolescents (Pediatric Clinical Chemistry) Distribution of Fasting Plasma Insulin, Free Fatty Acids, And Glucose Concentrations and of Homeostasis Model Assessment of Insulin Resistance in a Representative Sample of Quebec Children and Adolescents (Pediatric Clinical Chemistry)
2003
C677T and AI298C Polymorphisms of the Methylenetetrahydrofolate Reductase Gene: Incidence and Effect of Combined Genotypes on Plasma Fasting and Post-Methionine Load Homocysteine in Vascular Disease (Molecular Diagnostics and Genetics) C677T and AI298C Polymorphisms of the Methylenetetrahydrofolate Reductase Gene: Incidence and Effect of Combined Genotypes on Plasma Fasting and Post-Methionine Load Homocysteine in Vascular Disease (Molecular Diagnostics and Genetics)
2001
Acetylcholinesterase Activity and Biogenic Amines in Phenylketonuria (Technical Briefs) Acetylcholinesterase Activity and Biogenic Amines in Phenylketonuria (Technical Briefs)
2002
Homocysteine, 5, 10-Methylenetetrahydrofolate Reductase 677CT Polymorphism, Nutrient Intake, And Incident Cardiovascular Disease in 24 968 Initially Healthy Women (Molecular Diagnostics and Genetics) (Clinical Report) Homocysteine, 5, 10-Methylenetetrahydrofolate Reductase 677CT Polymorphism, Nutrient Intake, And Incident Cardiovascular Disease in 24 968 Initially Healthy Women (Molecular Diagnostics and Genetics) (Clinical Report)
2007